Affymax (AFFY +4%) makes new 52-week highs after Stifel upgrades shares to Buy. The firm expects...

|By:, SA News Editor

Affymax (AFFY +4%) makes new 52-week highs after Stifel upgrades shares to Buy. The firm expects Affymax's Peginesatide dialysis drug, which is set for a Q2 launch, to be "a disruptive force" in its target market, one that will put an end to the "monopoly pricing power" wielded by Amgen's (AMGN) Epogen.